MX2009011588A - Formas de dosificacion solidas que comprenden tadalafil. - Google Patents

Formas de dosificacion solidas que comprenden tadalafil.

Info

Publication number
MX2009011588A
MX2009011588A MX2009011588A MX2009011588A MX2009011588A MX 2009011588 A MX2009011588 A MX 2009011588A MX 2009011588 A MX2009011588 A MX 2009011588A MX 2009011588 A MX2009011588 A MX 2009011588A MX 2009011588 A MX2009011588 A MX 2009011588A
Authority
MX
Mexico
Prior art keywords
dosage forms
solid dosage
cialis
bioequivalent
tadalafil
Prior art date
Application number
MX2009011588A
Other languages
English (en)
Inventor
Ilan Zalit
Yonit Triger-Messer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2009011588A publication Critical patent/MX2009011588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas de dosificación farmacéuticas que comprenden tadalafil. Las formas de dosificación preferidas son bioequivaientes a Ciaiis¿ a pesar de tener un tamaño de partícula mayor.
MX2009011588A 2007-04-25 2008-04-25 Formas de dosificacion solidas que comprenden tadalafil. MX2009011588A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92640307P 2007-04-25 2007-04-25
US93144907P 2007-05-22 2007-05-22
PCT/US2008/061638 WO2008134557A2 (en) 2007-04-25 2008-04-25 Solid dosage forms

Publications (1)

Publication Number Publication Date
MX2009011588A true MX2009011588A (es) 2009-11-05

Family

ID=39529683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011588A MX2009011588A (es) 2007-04-25 2008-04-25 Formas de dosificacion solidas que comprenden tadalafil.

Country Status (12)

Country Link
US (1) US20090098211A1 (es)
EP (1) EP1985310B1 (es)
JP (1) JP2010525082A (es)
KR (1) KR20100012867A (es)
CN (1) CN101678114A (es)
AU (1) AU2008245597A1 (es)
BR (1) BRPI0810814A2 (es)
CA (1) CA2685184A1 (es)
ES (1) ES2405787T3 (es)
MX (1) MX2009011588A (es)
RU (1) RU2456989C2 (es)
WO (1) WO2008134557A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
EA201190091A1 (ru) * 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012095151A1 (en) * 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
EP2672959A1 (en) 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant
WO2013109223A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
WO2014092661A1 (en) * 2012-01-18 2014-06-19 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
US20160000720A1 (en) * 2013-02-14 2016-01-07 Aurobindo Pharma Limited Pharmaceutical compositions comprising Tadalafil
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR20150056443A (ko) * 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
WO2015072700A1 (en) * 2013-11-15 2015-05-21 Hanmi Pharm. Co., Ltd. Composite formulation comprising tadalafil and amlodipine
ES2699160T3 (es) * 2014-06-24 2019-02-07 Wooshin Labottach Co Ltd Formulación de película de desintegración oral que contiene tadalafilo y procedimiento de preparación de la misma
EP3466951B1 (en) 2014-07-23 2022-01-19 KRKA, d.d., Novo mesto A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates
KR101648051B1 (ko) 2014-09-01 2016-08-12 주식회사 인트로팜텍 타다라필을 포함하는 휴대용 구강붕해정, 및 이의 제조방법
KR101538985B1 (ko) * 2014-09-02 2015-07-24 주식회사 서울제약 타다라필 구강붕해필름 및 이의 제조방법
CN107303284A (zh) * 2016-04-25 2017-10-31 湖北生物医药产业技术研究院有限公司 制备他达拉非片剂的方法及他达拉非片剂
EA028561B1 (ru) * 2016-12-28 2017-11-30 Тева Фармасьютикал Индастриз, Лтд. Твердые лекарственные формы тадалафила
US20210137919A1 (en) * 2018-02-07 2021-05-13 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same
US10828254B2 (en) * 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US20220287979A1 (en) * 2019-08-08 2022-09-15 Evonik Operations Gmbh Method of preparing a solid dosage form and a lubricant
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
BR112023021236A2 (pt) * 2021-04-16 2023-12-12 Lg Chemical Ltd Formulação oral contendo ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
KR100738861B1 (ko) * 1999-08-03 2007-07-16 릴리 아이코스 엘엘씨 베타-카르볼린 약학 조성물
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
KR100666520B1 (ko) * 2002-02-07 2007-01-11 파마시아 코포레이션 점막 송달을 위한 약제학적 투약형
WO2005000296A1 (en) * 2002-08-30 2005-01-06 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276442A1 (en) * 2004-09-08 2006-12-07 Woodward John R Methods of female sexual enhancement
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CN1742732A (zh) * 2005-09-20 2006-03-08 杭州恒丰医药科技有限公司 西力士滴丸及其制备方法
US20080009502A1 (en) 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites

Also Published As

Publication number Publication date
AU2008245597A1 (en) 2008-11-06
ES2405787T3 (es) 2013-06-03
WO2008134557A2 (en) 2008-11-06
JP2010525082A (ja) 2010-07-22
BRPI0810814A2 (pt) 2014-10-29
WO2008134557A3 (en) 2009-02-05
CA2685184A1 (en) 2008-11-06
KR20100012867A (ko) 2010-02-08
RU2009141538A (ru) 2011-05-27
US20090098211A1 (en) 2009-04-16
EP1985310B1 (en) 2013-03-20
EP1985310A1 (en) 2008-10-29
CN101678114A (zh) 2010-03-24
RU2456989C2 (ru) 2012-07-27

Similar Documents

Publication Publication Date Title
MX2009011588A (es) Formas de dosificacion solidas que comprenden tadalafil.
GB0703507D0 (en) Solid pharmaceutical dose
ZA201005015B (en) Solid pharmaceutical dosage form
IL206159A0 (en) Oral pharmaceutical dosage forms
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
ME01580B (me) Farmaceutski dozni oblici
ZA201006029B (en) Pharmaceutical dosage form
IL185390A0 (en) A solid pharmaceutical dosage formulation
GB0721095D0 (en) Pharmaceutical compounds
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
IL194366A0 (en) Solid dosage formulations
IL204528A (en) Pharmaceutical dosage forms for immediate sustained release of metadoxin
ZA200903858B (en) Pharmaceutical dosage form
HK1137363A1 (en) Novel dosage form
GB0721669D0 (en) Pharmaceutical compounds
EP2211843B8 (en) Pharmaceutical moire pill
IL219617A0 (en) Pharmaceutical solid dosage form
ZA200803152B (en) Oramucosal pharmaceutical dosage form
EP2029116A4 (en) SECURE PHARMACEUTICAL FORMS
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
TR201005419A2 (tr) Valsartan içeren farmasötik bileşim.
ZA200810270B (en) Segmented pharmaceutical dosage forms
ZA200903855B (en) A pharmaceutical dosage form
GB0713093D0 (en) Pharmaceutical formulations
GB0723310D0 (en) Solid dosage vaccine